[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Articles

Page 1 of 41

  1. Degrader therapies have garnered significant attention for their innovative approach to targeting and eliminating malignancy-associated proteins, holding promise for improving outcomes for patients with relaps...

    Authors: Na Li, Jianpeng Sheng and Hong-Hu Zhu
    Citation: Journal of Hematology & Oncology 2025 18:26
    Content type: Correspondence Published on:

  3. Despite the success of immune checkpoint inhibitors (ICIs) in multiple malignant tumors, a significant proportion of patients remain unresponsive to treatment. Radiotherapy (RT) elicits immunogenic antitumor r...

    Authors: Yuze Wu, Yuheng Yan, Yarong Guo, Mengke Niu, Binghan Zhou, Jing Zhang, Pengfei Zhou, Qian Chu, Qi Mei, Ming Yi and Kongming Wu
    Citation: Journal of Hematology & Oncology 2025 18:24
    Content type: Research Published on:

  4. B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chime...

    Authors: Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Renyao Pan, Han Liu and Zhenshu Xu
    Citation: Journal of Hematology & Oncology 2025 18:23
    Content type: Correspondence Published on:

  5. Natural killer cells, integral to the innate immune response, exhibit the inherent capacity to identify and eliminate cancer cells without prior exposure, positioning them as prime candidates for immunotherape...

    Authors: Ran Kong, Bingyu Liu, Hua Wang, Tiange Lu and Xiangxiang Zhou
    Citation: Journal of Hematology & Oncology 2025 18:22
    Content type: Correspondence Published on:

  6. Authors: Le Qin, Yunxin Lai, Ruocong Zhao, Xinru Wei, Jianyu Weng, Peilong Lai, Baiheng Li, Simiao Lin, Suna Wang, Qiting Wu, Qiubin Liang, Yangqiu Li, Xuchao Zhang, Yilong Wu, Pentao Liu, Yao Yao…
    Citation: Journal of Hematology & Oncology 2025 18:21
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:68

  7. In the present era, noncoding RNAs (ncRNAs) have become a subject of considerable scientific interest, with peptides encoded by ncRNAs representing a particularly promising avenue of investigation. The identif...

    Authors: Shiming Tan, Wenjuan Yang, Zongyao Ren, Qiu Peng, Xuemeng Xu, Xianjie Jiang, Zhu Wu, Linda Oyang, Xia Luo, Jinguan Lin, Longzheng Xia, Mingjing Peng, Nayiyuan Wu, Yanyan Tang, Yaqian Han, Qianjin Liao…
    Citation: Journal of Hematology & Oncology 2025 18:20
    Content type: Review Published on:

  9. Cancer continues to be a major global health burden, with high morbidity and mortality. Building on the success of immune checkpoint inhibitors and adoptive cellular therapy, cancer vaccines have garnered sign...

    Authors: Yingqiong Zhou, Yuquan Wei, Xiaohe Tian and Xiawei Wei
    Citation: Journal of Hematology & Oncology 2025 18:18
    Content type: Review Published on:

  10. Cytokine induced memory-like natural killer (CIML NK) cells combined with an IL-15 super-agonist (N-803) are a novel modality to treat relapsed/refractory head and neck cancer.

    Authors: Roman M. Shapiro, Michal Sheffer, Matthew A. Booker, Michael Y. Tolstorukov, Grace C. Birch, Moshe Sade-Feldman, Jacy Fang, Shuqiang Li, Wesley Lu, Michela Ansuinelli, Remy Dulery, Mubin Tarannum, Joanna Baginska, Nishant Dwivedi, Ashish Kothari, Livius Penter…
    Citation: Journal of Hematology & Oncology 2025 18:17
    Content type: Research Published on:

  11. Natural products have long been a viable source of therapeutic agents, providing unique structures and mechanisms that may be beneficial for cancer treatment. Herein we first report on the anticancer activity ...

    Authors: HyunJun Kang, Dinh Hoa Hoang, Melissa Valerio, Khyatiben Pathak, William Graff, Alexis LeVee, Jun Wu, Mark A. LaBarge, David Frankhouser, Russell C. Rockne, Patrick Pirrotte, Bin Zhang, Joanne Mortimer, Le Xuan Truong Nguyen and Guido Marcucci
    Citation: Journal of Hematology & Oncology 2025 18:16
    Content type: Correspondence Published on:

  12. Open-label phase Ib/II study to investigate the safety and efficacy of LBL-007, an anti-LAG-3 antibody, plus toripalimab, an anti-PD-1 antibody, in patients with previously treated advanced nasopharyngeal carc...

    Authors: Gang Chen, Dong-Chen Sun, Yi Ba, Ya-Xiong Zhang, Ting Zhou, Yuan-Yuan Zhao, Hong-Yun Zhao, Wen-Feng Fang, Yan Huang, Zhen Wang, Chao Deng, De-Sheng Hu, Wei Wang, Jin-Guan Lin, Gui-Ling Li, Su-Xia Luo…
    Citation: Journal of Hematology & Oncology 2025 18:15
    Content type: Research Published on:

  13. Small cell lung cancer (SCLC) is an aggressive and heterogeneous subtype, representing 15% of lung cancer cases. Although SCLC initially responds to etoposide and platinum (EP) chemotherapy, nearly all patient...

    Authors: Seungyeul Yoo, Ayushi S. Patel, Sarah Karam, Yi Zhong, Li Wang, Feng Jiang, Ranran Kong, Sharon Bikvan, Wenhui Wang, Abhilasha Sinha, Charles A. Powell, Jun Zhu and Hideo Watanabe
    Citation: Journal of Hematology & Oncology 2025 18:14
    Content type: Correspondence Published on:

  15. N7-methylguanosine (m7G) is an important RNA modification involved in epigenetic regulation that is commonly observed in both prokaryotic and eukaryotic organisms. Their influence on the synthesis and processi...

    Authors: Qihui Wu, Xiaodan Fu, Guoqian Liu, Xiaoyun He, Yimin Li and Chunlin Ou
    Citation: Journal of Hematology & Oncology 2025 18:12
    Content type: Review Published on:

  16. Authors: Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger…
    Citation: Journal of Hematology & Oncology 2025 18:11
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2024 17:128

  18. Cell therapies, including tumor antigen-loaded dendritic cells used as therapeutic cancer vaccines, offer treatment options for patients with malignancies. We evaluated the feasibility, safety, immunogenicity,...

    Authors: Zwi N. Berneman, Maxime De Laere, Paul Germonpré, Manon T. Huizing, Yannick Willemen, Eva Lion, Hans De Reu, Jolien Van den Bossche, Jan Van den Brande, Pol Specenier, Sevilay Altintas, Peter A. van Dam, Nathalie Cools, Griet Nijs, Barbara Stein, Kim Caluwaerts…
    Citation: Journal of Hematology & Oncology 2025 18:9
    Content type: Correspondence Published on:

  19. Reovirus (RV) is an oncolytic virus with natural tropism for cancer cells. We previously showed that RV administration in multiple myeloma (MM) patients was safe, but disease control associated with viral repl...

    Authors: Ada Alice Dona, Theophilus Tandoh, Lokesh Nigam, Mahmoud Singer, Enrico Caserta, Mariam Murtadha, Yinghui Zhu, Milad Moloudizargari, Preeti Sharma, Ottavio Napolitano, Janet Winchester, Arnab Chowdhury, Alex Pozhitkov, James F. Sanchez, Hawa Vahed, Guido Marcucci…
    Citation: Journal of Hematology & Oncology 2025 18:1
    Content type: Research Published on:

  20. Anti-CD19 chimeric antigen receptor T cells (CAR) are a well-established treatment option for children and young adults suffering from relapsed/refractory B-lineage acute lymphoblastic leukemia. Bridging thera...

    Authors: Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Coffey, Arend von Stackelberg…
    Citation: Journal of Hematology & Oncology 2025 18:8
    Content type: Correspondence Published on:

  21. Olutasidenib is a potent, selective, oral, small molecule inhibitor of mutant IDH1 (mIDH1) which induced durable remissions in high-risk, relapsed/refractory (R/R) mIDH1 AML patients in a phase 1/2 trial. We pres...

    Authors: Jorge E. Cortes, Gail J. Roboz, Maria R. Baer, Brian A. Jonas, Gary J. Schiller, Karen Yee, P. Brent Ferrell, Jay Yang, Eunice S. Wang, William G. Blum, Alice Mims, Hua Tian, Aaron Sheppard, Stéphane de Botton, Pau Montesinos, Antonio Curti…
    Citation: Journal of Hematology & Oncology 2025 18:7
    Content type: Research Published on:

  22. The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, and signaling molecules that...

    Authors: Antonino Glaviano, Hannah Si-Hui Lau, Lukas M. Carter, E. Hui Clarissa Lee, Hiu Yan Lam, Elena Okina, Donavan Jia Jie Tan, Wency Tan, Hui Li Ang, Daniela Carbone, Michelle Yi-Hui Yee, Muthu K. Shanmugam, Xiao Zi Huang, Gautam Sethi, Tuan Zea Tan, Lina H. K. Lim…
    Citation: Journal of Hematology & Oncology 2025 18:6
    Content type: Review Published on:

  23. Female-specific cancers, particularly breast, cervical, ovarian, and uterine cancers, account for nearly 40% of all cancers in women. This study aimed to analyze the global epidemiological trends of these canc...

    Authors: Tianye Li, Haoxiang Zhang, Mengyi Lian, Qionghua He, Mingwei Lv, Lingyun Zhai, Jianwei Zhou, Kongming Wu and Ming Yi
    Citation: Journal of Hematology & Oncology 2025 18:5
    Content type: Research Published on:

  24. Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma rarely presents with circulating lymphoma cells (CL) at diagnosis. Previous studies were limited by small sample size precludi...

    Authors: Sayan Mullick Chowdhury, Subodh Bhatta, Timothy J. Voorhees, Kaitlin Annunzio, David A. Bond, Yazeed Sawalha, Audrey Sigmund, Walter Hanel, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Kami Maddocks, Beth Christian, Dan Jones and Narendranath Epperla
    Citation: Journal of Hematology & Oncology 2025 18:4
    Content type: Correspondence Published on:

  25. The study is to evaluate the efficacy and safety of combined anlotinib and EGFR-tyrosine kinase inhibitors (TKIs) in patients with advanced non-small cell lung cancer (NSCLC) who had gradual, oligo, or potenti...

    Authors: Hua-Jun Chen, Hai-Yan Tu, Yanping Hu, Yun Fan, Guowu Wu, Shundong Cang, Yi Yang, Nong Yang, Rui Ma, Gaowa Jin, Ximing Xu, Anwen Liu, Shubin Tang, Ying Cheng, Yan Yu, Chong-Rui Xu…
    Citation: Journal of Hematology & Oncology 2025 18:3
    Content type: Research Published on:

  26. Targeting glucose uptake by glucose transporter (GLUT) inhibitors is a therapeutic opportunity, but efforts on GLUT inhibitors have not been successful in the clinic and the underlying mechanism remains unclea...

    Authors: Cheng-E Tu, Yong-Feng Liu, Hong-Wei Liu, Chun-Mei Jiao, Quentin Liu, Mien-Chie Hung, Peng Li, Xiang-Bo Wan, Xin-Juan Fan and Yun-Long Wang
    Citation: Journal of Hematology & Oncology 2025 18:2
    Content type: Research Published on:

  27. Co-inhibition of immune checkpoints lymphocyte-activation gene 3 (LAG-3) and PD-1 is believed to enhance cancer immunotherapy through synergistic effects. Herein, we evaluate the safety and efficacy of IBI110 ...

    Authors: Chenyu Mao, Anwen Xiong, Jiong Qian, Wenxiang Wang, Ying Liu, Tao Zhang, Zhihai Wu, Haiqing Ni, Jia Lu, Sixiang Long, Li Zhao, Yuling Chen, Caicun Zhou and Nong Xu
    Citation: Journal of Hematology & Oncology 2024 17:132
    Content type: Research Published on:

  28. Substantial therapeutic advancement has been made in the field of immunotherapy in breast cancer. The immune checkpoint inhibitor pembrolizumab in combination with chemotherapy received FDA approval for both P...

    Authors: Natalie K. Heater, Surbhi Warrior and Janice Lu
    Citation: Journal of Hematology & Oncology 2024 17:131
    Content type: Review Published on:

  29. Lenvatinib is a multi-target tyrosine kinase inhibitor widely used in the treatment of hepatocellular carcinoma (HCC). Its primary mechanism of action involves inhibiting signal pathways such as vascular endot...

    Authors: Yuhang Chen, Suoyi Dai, Chien-shan Cheng and Lianyu Chen
    Citation: Journal of Hematology & Oncology 2024 17:130
    Content type: Review Published on:

  30. Authors: Yan Bian, Ye Gao, Han Lin, Chang Sun, Wei Wang, Siyu Sun, Xiuling Li, Zhijie Feng, Jianlin Ren, Hezhong Chen, Chaojing Lu, Jinfang Xu, Jun Zhou, Kangkang Wan, Lei Xin, Zhaoshen Li…
    Citation: Journal of Hematology & Oncology 2024 17:129
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2024 17:47

  31. Accumulation of malignant plasma cells in the bone marrow causes lytic bone lesions in 80% of multiple myeloma patients. Frequently fracturing, they are challenging to treat surgically. Myeloma cells surviving...

    Authors: Dirk Hose, Seemun Ray, Sina Rößler, Ulrich Thormann, Reinhard Schnettler, Kim de Veirman, Thaqif El Khassawna, Christian Heiss, Anne Hild, Daniel Zahner, Francisca Alagboso, Anja Henss, Susanne Beck, Martina Emde-Rajaratnam, Jürgen Burhenne, Juliane Bamberger…
    Citation: Journal of Hematology & Oncology 2024 17:128
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2025 18:11

  32. Sarcomas are rare, mesenchymal tumors, representing about 10–15% of all childhood cancers. GD2 is a suitable target for chimeric antigen receptor (CAR) T-cell therapy due to its overexpression in several solid...

    Authors: Michele Pezzella, Concetta Quintarelli, Maria C. Quadraccia, Andrea Sarcinelli, Simona Manni, Laura Iaffaldano, Alessio Ottaviani, Roselia Ciccone, Antonio Camera, Maria L. D’Amore, Stefano Di Cecca, Matilde Sinibaldi, Marika Guercio, Mariasole Aurigemma, Pamela De Falco, Valentina Fustaino…
    Citation: Journal of Hematology & Oncology 2024 17:127
    Content type: Research Published on:

  33. Liver metastasis from colorectal cancer (CRC) is a major clinical challenge that severely affects patient survival. myofibroblastic cancer-associated fibroblasts (myCAFs) are a major component of the CRC tumor...

    Authors: Hongsheng Fang, Weixing Dai, Ruiqi Gu, Yanbo Zhang, Jin Li, Wenqin Luo, Shanyou Tong, Lingyu Han, Yichao Wang, Chengyao Jiang, Xue Wang, Renjie Wang and Guoxiang Cai
    Citation: Journal of Hematology & Oncology 2024 17:126
    Content type: Research Published on:

  34. Up to 65% of patients with chronic myeloid leukemia (CML) who are treated with imatinib do not achieve sustained deep molecular response, which is required to attempt treatment-free remission. Asciminib is the...

    Authors: Timothy P. Hughes, Giuseppe Saglio, Jan Geissler, Dong-Wook Kim, Elza Lomaia, Jiri Mayer, Anna Turkina, Shruti Kapoor, Ana Paula Cardoso, Becki Nieman, Sara Quenet and Jorge E. Cortes
    Citation: Journal of Hematology & Oncology 2024 17:125
    Content type: Research Published on:

  36. Amulirafusp alfa (IMM0306) is a fusion protein of CD47 binding domain of signal-regulatory protein alpha (SIRPα) with CD20 monoclonal antibody on both heavy chains. This study aimed to evaluate the safety and ...

    Authors: Jianliang Yang, Yongping Song, Keshu Zhou, Zhiming Li, Mingzhi Zhang, Hongmei Jing, Zhen Wang, Li Yu, Wei Meng, Qiying Lu, Wenzhi Tian and Yuankai Shi
    Citation: Journal of Hematology & Oncology 2024 17:123
    Content type: Research Published on:

  37. As one of the most promising adoptive cell therapies, CAR-T cell therapy has achieved notable clinical effects in patients with hematological tumors. However, several treatment-related obstacles remain in CAR-...

    Authors: Yue Liu, Lingna An, Xiaoqi Wang, Yueyu Dai, Cheng Zhang, Qin Wen and Xi Zhang
    Citation: Journal of Hematology & Oncology 2024 17:122
    Content type: Research Published on:

  39. Chimeric antigen receptor (CAR)-T cell therapy has emerged as one of the most rapidly evolving modalities of immunotherapy, with substantial success in the treatment of hematological malignancies and encouragi...

    Authors: Huageng Huang, Le Yu, Huawei Weng, Wei Zhang, Zhao Wang, Lin Wang and He Huang
    Citation: Journal of Hematology & Oncology 2024 17:120
    Content type: Correspondence Published on:

  40. Cancer is the second most common cause of death globally. Therefore, it is imperative to investigate cancer incidence, mortality rates, and disability-adjusted life years (DALYs) to enhance preventive measures...

    Authors: Zenghong Wu, Fangnan Xia and Rong Lin
    Citation: Journal of Hematology & Oncology 2024 17:119
    Content type: Research Published on:

  41. There is an unmet clinical need to enhance the response rate and safety of anti-PD-1/PD-L1-based cancer immunotherapy (IO). Herein, we presented the clinical study of IBI318 (LY3434172), a first-in-class bispe...

    Authors: Dan-Yun Ruan, Xiao-Li Wei, Fu-Rong Liu, Xi-Chun Hu, Jian Zhang, Dong-Mei Ji, Ding-Zhi Huang, Yan-Qiu Zhao, Hong-Min Pan, Wang-Jun Liao, Kun-Yu Yang, Nong Xu, Xiao-Xiao Lu, Yu-Ling Chen, Wen Zhang, Hui Zhou…
    Citation: Journal of Hematology & Oncology 2024 17:118
    Content type: Research Published on:

  42. Immunotherapy resistance in bladder cancer (BLCA) is associated with elevated levels of sialic acid–binding immunoglobulin-like lectin (Siglec15). This protein plays a crucial role in fostering a noninflammato...

    Authors: Dingshan Deng, Jiatong Xiao, Jinhui Liu, Huihuang Li, Minghui Hu, Bohan Zhou, Haisu Liang, Benyi Fan, Jinbo Chen, Xiaogen Kuang, Zhenyu Nie, Jiao Hu and Xiongbing Zu
    Citation: Journal of Hematology & Oncology 2024 17:117
    Content type: Correspondence Published on:

  43. CAR-macrophage has promising prospect in treating solid tumors, due to its high infiltration into tumors, and its dual roles in phagocytosis and immune modulation. Here we show the clinical results of CAR-macr...

    Authors: Xiumin Li, Xudong Wang, Hao Wang, Donghua Zuo, Jianpo Xu, Yixuan Feng, Dixuan Xue, Li Zhang, Lin Lin and Jin Zhang
    Citation: Journal of Hematology & Oncology 2024 17:116
    Content type: Correspondence Published on:

  44. Cancer vaccines have garnered attention as a potential treatment for cancer metastases. Nevertheless, the clinical response rate to vaccines remains < 30%. Nanoparticles stabilize vaccines and improve antigen ...

    Authors: Tang Feng, Jia Hu, Jirui Wen, Zhiyong Qian, Guowei Che, Qinghua Zhou and Lingling Zhu
    Citation: Journal of Hematology & Oncology 2024 17:115
    Content type: Review Published on:

  45. Lung adenocarcinoma (LUAD) is one of the leading causes of cancer-related deaths worldwide, with a 5-year survival rate of approximately 19%. With the advent of screening and diagnostic techniques such as low-...

    Authors: Qi Zhang, Xiaoli Zhang, Zhuoheng Lv, Huandong Huo, Ligong Yuan, Duo Wan, Peipei Xie, Shujun Cheng, Kaitai Zhang, Wen Zhang and Yousheng Mao
    Citation: Journal of Hematology & Oncology 2024 17:114
    Content type: Correspondence Published on:

  46. The AML treatment landscape has significantly changed in recent years with the approval of targeted therapies in the front-line and relapsed/refractory settings, including inhibitors of FLT3 and IDH1/2 mutatio...

    Authors: Kalyan V. G. Nadiminti, Kieran D. Sahasrabudhe and Hongtao Liu
    Citation: Journal of Hematology & Oncology 2024 17:113
    Content type: Review Published on:

  47. The outcomes of patients with acute myeloid leukemia (AML) and bone marrow fibrosis (MF) are not well defined. The study objectives were to evaluate the degrees of MF in AML, and corresponding response rates a...

    Authors: Samuel Urrutia, Hagop M. Kantarjian, Farhad Ravandi-Kashani, Carlos Bueso-Ramos, Rashmi Kanagal-Shamanna, Elias Jabbour, Guillermo Montalban-Bravo, Nicholas J. Short, Naval Daver, Gautam Borthakur, Courtney D. Dinardo, Tapan M. Kadia, Lucia Masarova, Prithviraj Bose, Naveen Pemmaraju, Guillermo Garcia-Manero…
    Citation: Journal of Hematology & Oncology 2024 17:112
    Content type: Research Published on:

  49. Chimeric antigen receptor (CAR) cell therapy has achieved groundbreaking success in treating hematological malignancies. However, its application to solid tumors remains challenging due to complex manufacturin...

    Authors: Weiyue Zhang and Xin Huang
    Citation: Journal of Hematology & Oncology 2024 17:110
    Content type: Review Published on:

  50. Though several anti-PD-1/PD-L1 antibodies approved for monotherapy in microsatellite instability-high or mismatch repair-deficient unresectable/metastatic solid tumors, novel immunotherapy with better anti-tum...

    Authors: Feng Bi, Jian Dong, Chuan Jin, Zuoxing Niu, Wenhui Yang, Yifu He, Dajun Yu, Meili Sun, Teng Wang, Xianli Yin, Ruixing Zhang, Kehe Chen, Keming Wang, Zhiwu Wang, Wei Li, Zhongtao Zhang…
    Citation: Journal of Hematology & Oncology 2024 17:109
    Content type: Correspondence Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • Citation Impact 2023
    Journal Impact Factor: 29.9
    5-year Journal Impact Factor: 27.1
    Source Normalized Impact per Paper (SNIP): 4.489
    SCImago Journal Rank (SJR): 7.522

    Speed 2024
    Submission to first editorial decision (median days): 4
    Submission to acceptance (median days): 61

    Usage 2024
    Downloads: 3,430,659
    Altmetric mentions: 1,308

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us